<DOC>
	<DOCNO>NCT01991977</DOCNO>
	<brief_summary>This phase II trial study well fluorine F 18 fluorodopa ( 18F-DOPA ) -positron emission tomography ( PET ) work find tumor patient newly diagnose glioma undergo radiation therapy . Comparing result diagnostic procedure do radiation therapy may help doctor predict patient 's response treatment help plan best treatment .</brief_summary>
	<brief_title>18F-DOPA-PET Finding Tumors Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare progression free survival 12 month grade IV glioma patient radiation therapy target volume design 18F-DOPA PET conventional magnetic resonance ( MR ) image information historical control Mayo Clinic Rochester patient treat North Central Cancer Treatment Group ( NCCTG ) clinical trial . SECONDARY OBJECTIVES : I . Compare progression free survival 12 month grade III patient radiation therapy target volume design 18F-DOPA PET conventional MR image information historical control Mayo Clinic Rochester patient NCCTG clinical trial . II . Compare patient outcomes include overall survival radiation therapy target volume design 18F-DOPA PET conventional MR image information historical control Mayo Clinic Rochester patient NCCTG clinical trial . III . Evaluate quality life radiotherapy treatment target dose escalate volume define include high 18F-DOPA PET uptake . IV . Determine acute late effect toxicity radiotherapy treatment target dose escalate volume define include high 18F-DOPA PET uptake . TERTIARY OBJECTIVES : I . Compare radiation therapy ( RT ) treatment volume define MR RT treatment volume define PET MR information grade IV glioma patient . II . Compare time accurate identification progression define 18F-DOPA PET , perfusion MRI ( pMRI ) conventional MRI grade IV glioma patient . III . Compare pattern failure radiation therapy target volume define target volume design 18F-DOPA PET conventional MR image information pattern failure historical control Mayo Clinic Rochester patient NCCTG clinical trial . IV . Compare RT treatment volume define MR RT treatment volume define PET MR information grade III glioma patient . V. Evaluate intra- inter-observer variability vs. without addition 18F-DOPA PET uptake radiotherapy target volume delineation . VI . Compare time accurate identification progression define 18F-DOPA PET , pMRI conventional MRI grade III glioma patient . VII . Compare predictive capability 18F-DOPA PET , pMRI diffusion tensor imaging ( DTI ) localization recurrences patient treat 18F-DOPA PET-guided RT dose escalation . OUTLINE : Patients undergo 18F DOPA-PET , pMRI , DTI within 14 day radiation therapy , 3-6 week radiation therapy , follow-up . Patients also undergo intensity-modulated radiation therapy ( IMRT ) 30 fraction receive temozolomide . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Dihydroxyphenylalanine</mesh_term>
	<criteria>Histologically confirm newly diagnose highgrade malignant glioma Planned radiation treatment Mayo Clinic Rochester Provide write informed consent Ability complete questionnaire ( ) assistance Patients diagnose anaplastic oligodendroglioma Unable undergo MRI scan contrast ( e.g . cardiac pacemaker , defibrillator , kidney failure ) Unable undergo 18FDOPA PET scan ( e.g . Parkinson 's disease , take antidopaminergic , dopamine agonist medication le 6 halflives discontinuance dopamine agonist ; potentially interfere drug consist : amoxapine , amphetamine , benztropine , buproprion , buspirone , cocaine , mazindol , methamphetamine , methylphenidate , norephedrine , phentermine , phenylpropanolamine , selegiline , paroxetine , citalopram , sertraline ) Any follow : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>